Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib preclinical study

Hypertension

Volumn 64, Issue 6, 2014, Pages 1282-1289

  Lankhorst, Stephanie ^a   Kappers, Mariëtte H W ^a,d   Van Esch, Joep H M ^a   Smedts, Frank M M ^c   Sleijfer, Stefan ^b   Mathijssen, Ron H J ^b   Baelde, Hans J ^e   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d AMPHIA HOSPITAL   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute renal injury; Endothelin 1; Hypertension; Sunitinib; Therapeutics; Vascular endothelial growth factor A

Indexed keywords

AMLODIPINE; CAPTOPRIL; MACITENTAN; SILDENAFIL; SUNITINIB; ANGIOGENESIS INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENDOTHELINURIA; HYPERTENSION; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; RAT; TELEMETRY; URINALYSIS; URINARY TRACT DISEASE; ACUTE KIDNEY INJURY; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY; TREATMENT OUTCOME; WISTAR KYOTO RAT;

ACUTE KIDNEY INJURY; AMLODIPINE; ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIN A RECEPTOR ANTAGONISTS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HYPERTENSION; INDOLES; PYRIMIDINES; PYRROLES; RATS; RATS, INBRED WKY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84922481556     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04187     Document Type: Article

References (40)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475-485.
3. Kappers MH, Van Esch JH, Sleijfer S, Danser AH, Van Den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens. 2009;27:2297-2309.
4. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-193.
5. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-731.
6. Kappers MH, Van Esch JH, Sluiter W, Sleijfer S, Danser AH, Van Den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675-681.
7. Kappers MH, Smedts FM, Horn T, Van Esch JH, Sleijfer S, Leijten F, Wesseling S, Strevens H, Jan Danser AH, Van Den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295-302.
8. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011-1021.
9. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfeld J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M. Pharmacology of macitentan, an orally active tissuetargeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736-745.
10. Franklin PH, Banfor PN, Tapang P, Segreti JA, Widomski DL, Larson KJ, Noonan WT, Gintant GA, Davidsen SK, Albert DH, Fryer RM, Cox BF. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N'-(2-fuoro-5-methylphenyl) urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009;329:928-937.
11. Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol. 2009;297:F802-F808.
12. Nagasawa T, Hye Khan MA, Imig JD. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 2012;39:454-461.
13. Van Esch JH, Moltzer E, Van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens. 2010;28:2145-2155.
14. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol. 2007;150:567-576.
15. Attia DM, Verhagen AM, Stroes ES, Van Faassen EE, Gröne HJ, De Kimpe SJ, Koomans HA, Braam B, Joles JA. Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2001;12:2585-2593.
16. De Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010;51:934-941.
17. Eechoute K, Van Der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, Van Herpen CM, Haanen JB, Mathijssen RH, Boven E. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92:503-510.
18. Bae EH, Kim IJ, Joo SY, Kim EY, Kim CS, Choi JS, Ma SK, Kim SH, Lee JU, Kim SW. Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res. 2012;36:248-257.
19. Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulindependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol. 2011;162:1389-1400.
20. Macconi D, Sangalli F, Bonomelli M, Conti S, Condorelli L, Gagliardini E, Remuzzi G, Remuzzi A. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol. 2009;174:797-807.
21. Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother. 2010;11:2651-2663.
22. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 2008;14:3124-3131.
23. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1363-1369.
24. Facemire CS, Nixon AB, Griffths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652-658.
25. Gennari-Moser C, Khankin EV, Escher G, Burkhard F, Frey BM, Karumanchi SA, Frey FJ, Mohaupt MG. Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension. 2013;61:1111-1117.
26. Lankhorst S, Kappers MH, Van Esch JH, Danser AH, Van Den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31:444-54.
27. Lankhorst S, Kappers MH, Van Esch JH, Danser AH, Van Den Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20:135-145.
28. Thijs AM, Van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, Van Der Graaf WT, Rongen GA. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61:1060-1065.
29. Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitorinduced hypertension. Angiogenesis. 2013;16:289-295.
30. Dhaun N, Webb DJ, Kluth DC. Endothelin-1 and the kidney-beyond BP. Br J Pharmacol. 2012;167:720-731.
31. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997;29:2-26.
32. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi G. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008;294:F1185-F1194.
33. Hauser PV, Collino F, Bussolati B, Camussi G. Nephrin and endothelial injury. Curr Opin Nephrol Hypertens. 2009;18:3-8.
34. Langenberg MH, Van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152-6159.
35. Verhoest G, Dolley-Hitze T, Jouan F, Belaud-Rotureau MA, Oger E, Lavenu A, Bensalah K, Arlot-Bonnemains Y, Collet N, Rioux-Leclercq N, Vigneau C. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. Biomed Res Int. 2014;2014:901371.
36. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, Gintant GA. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173-178.
37. Bagnato A, Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40:1443-1451.
38. Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E. Targeting the endothelin axis in prostate carcinoma. Tumour Biol. 2012;33:421-426.
39. Groenewegen G, Walraven M, Vermaat J, De Gast B, Witteveen E, Giles R, Haanen J, Voest E. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer. 2012;106:284-289.
40. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423-1431.